Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G

2010 ◽  
Vol 103 (9) ◽  
pp. 856-863 ◽  
Author(s):  
Melvin Berger ◽  
Elyse Murphy ◽  
Patty Riley ◽  
Garrett E. Bergman
Keyword(s):  
Quality Of Life ◽  
Primary Immunodeficiency ◽  
Immunoglobulin G ◽  
Subcutaneous Immunoglobulin ◽  
Primary Immunodeficiency Diseases ◽  
Infection Rates ◽  
Immunodeficiency Diseases

Subcutaneous immunoglobulin substitution and therapy

2011 ◽  
Vol 152 (2) ◽  
pp. 64-67
Author(s):  
Vera Gulácsy ◽  
László Maródi
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Immunoglobulin G ◽  
Subcutaneous Immunoglobulin ◽  
The Past ◽  
Ivig Replacement ◽  
B Cell Deficiency ◽  
Igg Level ◽  
Low Serum

Patients with combined primary immunodeficiency or B-cell deficiency with low serum concentration of immunoglobulin G can be efficiently treated with immunoglobulin G concentrates. From the 1950s IgG was used intramuscularly, and from the 1980s intravenous immunoglobulin (IVIG) replacement has become widely available for replacement therapy. Among the potential side effects of IVIG (including anaphylaxis), further disadvantages of IVIG are hospitalization during treatment and varying concentrations of IgG. Over the past ten years, subcutaneous IgG (SCIG) preparations have become reasonable alternatives to IVIG. SCIG given weekly assures a more balanced serum IgG level, side affects are mostly local and temporary, systemic, severe adverse events have not been observed. In addition, SCIG can be used for home treatment of patients which improves their quality of life remarkably. Orv. Hetil., 2011, 152, 64–67.

Sign in / Sign up

Export Citation Format

Share Document